Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)

BACKGROUND: Despite major improvements in the perioperative outcome of pancreas surgery, the prognosis of pancreatic cancer after curative resection remains poor. Adjuvant chemotherapy increases disease-free and overall survival, but this treatment cannot be offered to a significant proportion of pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinrich, Stefan, Pestalozzi, Bernhard, Lesurtel, Mickael, Berrevoet, Frederik, Laurent, Stéphanie, Delpero, Jean-Robert, Raoul, Jean-Luc, Bachellier, Phillippe, Dufour, Patrick, Moehler, Markus, Weber, Achim, Lang, Hauke, Rogiers, Xavier, Clavien, Pierre-Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176241/
https://www.ncbi.nlm.nih.gov/pubmed/21831266
http://dx.doi.org/10.1186/1471-2407-11-346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176241/
https://www.ncbi.nlm.nih.gov/pubmed/21831266
http://dx.doi.org/10.1186/1471-2407-11-346

Ejemplares similares